Access to hepatitis C treatment: a lesson for the future

Research output: Contribution to journalArticle

Abstract

The new generation of direct acting antivirals (DAA) for the treatment of chronic hepatitis C virus infection has revolutionized the previous scenario and has put the institutions under test because of the high cost of therapies. An analysis of what has happened over the last three years, especially in Italy, helps us understand how price negotiation has been managed, and what criteria were chosen at first to allow limited access on the basis of the need of patient care. This allows to focus on some important issues and to identify the challenges ahead in the near future.
Original languageEnglish
Pages (from-to)25-27
Number of pages3
JournalRECENTI PROGRESSI IN MEDICINA
Volume109
Publication statusPublished - 2018

Fingerprint

Hepatitis C
Negotiating
Chronic Hepatitis C
Virus Diseases
Hepacivirus
Italy
Antiviral Agents
Patient Care
Costs and Cost Analysis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Access to hepatitis C treatment: a lesson for the future. / Craxi', Lucia.

In: RECENTI PROGRESSI IN MEDICINA, Vol. 109, 2018, p. 25-27.

Research output: Contribution to journalArticle

@article{1f1be02258a84d40b1ba9bb67bf5ddea,
title = "Access to hepatitis C treatment: a lesson for the future",
abstract = "The new generation of direct acting antivirals (DAA) for the treatment of chronic hepatitis C virus infection has revolutionized the previous scenario and has put the institutions under test because of the high cost of therapies. An analysis of what has happened over the last three years, especially in Italy, helps us understand how price negotiation has been managed, and what criteria were chosen at first to allow limited access on the basis of the need of patient care. This allows to focus on some important issues and to identify the challenges ahead in the near future.",
author = "Lucia Craxi'",
year = "2018",
language = "English",
volume = "109",
pages = "25--27",
journal = "RECENTI PROGRESSI IN MEDICINA",
issn = "2038-1840",

}

TY - JOUR

T1 - Access to hepatitis C treatment: a lesson for the future

AU - Craxi', Lucia

PY - 2018

Y1 - 2018

N2 - The new generation of direct acting antivirals (DAA) for the treatment of chronic hepatitis C virus infection has revolutionized the previous scenario and has put the institutions under test because of the high cost of therapies. An analysis of what has happened over the last three years, especially in Italy, helps us understand how price negotiation has been managed, and what criteria were chosen at first to allow limited access on the basis of the need of patient care. This allows to focus on some important issues and to identify the challenges ahead in the near future.

AB - The new generation of direct acting antivirals (DAA) for the treatment of chronic hepatitis C virus infection has revolutionized the previous scenario and has put the institutions under test because of the high cost of therapies. An analysis of what has happened over the last three years, especially in Italy, helps us understand how price negotiation has been managed, and what criteria were chosen at first to allow limited access on the basis of the need of patient care. This allows to focus on some important issues and to identify the challenges ahead in the near future.

UR - http://hdl.handle.net/10447/279842

M3 - Article

VL - 109

SP - 25

EP - 27

JO - RECENTI PROGRESSI IN MEDICINA

JF - RECENTI PROGRESSI IN MEDICINA

SN - 2038-1840

ER -